Medigene AG: Medigene AG Expands Patent Portfolio with Patent Grant for its MAGE-A4 Targeted T Cell Receptor in Japan

Planegg/Martinsried (pta020/14.01.2025/11:00) - Medigene AG ( http://www.medigene.com ) (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today that the Japan Patent Office has issued a patent for its T cell receptor (TCR) targeting MAGE-A4, a well-established and validated cancer-testis antigen, found in various tumor types.

"We are delighted that the Japan Patent Office has granted a patent for our MAGE-A4-targeted TCR," said Selwyn Ho, CEO of Medigene AG. "This patent builds on our existing portfolio, which includes similar grants in China and Eurasia. Our 3S TCRs—designed to be sensitive, specific, and safe—are versatile and can be utilized across a variety of TCR-guided modalities, including off-the-shelf TCR-guided T cell engagers, TCR-guided natural killer cell therapies, and TCR-T therapies. This patent strengthens our global position and reinforces our commitment to advancing innovative solutions in immunotherapy."

Medigene continually strengthens and expands its patent portfolio by developing innovative 3S TCRs, integrating advanced technologies, and extending existing patents to additional jurisdictions. The company currently owns over 29 unique patent families worldwide, protecting its 3S TCRs and exclusive E2E Platform technologies.

--- end of press release ---

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that can be utilized in multiple therapeutic modalities, such as off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010), TCR-natural killer cell (TCR-NK) therapies and T cell receptor engineered T cell (TCR-T) therapies (MDG1015). For more information, please visit https://medigene.com/

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(Ende)